Food, drugs, devices › Preferred Pharmaceuticals, Inc.
Drug recall: Atorvastatin Calcium Tablets, USP, 10 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27
FDA enforcement event 91952 is a drug recall by Preferred Pharmaceuticals, Inc. of Anaheim, CA, initiated 23 Mar 2023 and classified Class II, with 17 product records.
FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 59% of the 281 drug enforcement events initiated in 2023 carry the same class.
Status: Ongoing. Initiation: voluntary: firm initiated. Preferred Pharmaceuticals, Inc. has 32 enforcement events on this register, with a median of 1 product record per event.
Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.
Recalling firm
Preferred Pharmaceuticals, Inc., Anaheim, CA.
Reason for recall
"cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection."
Distribution
"USA Nationwide"
Product records
| Recall number | Product | Quantity | Class | Status | Report date |
|---|---|---|---|---|---|
| D-0511-2023 | Atorvastatin Calcium Tablets, USP, 10 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-7630-9 | 158 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0512-2023 | Atorvastatin Calcium Tablets, USP, 20 mg, packaged in: a) 90-count bottle (NDC 68788-7631-9); b) 30-count bottle (NDC 68788-7631-3), Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703 | a) 375 Bottles b) 323 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0513-2023 | Clopidogrel Tablets USP, 75 mg, 90-count bottles, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-8190-9 | 72 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0514-2023 | Doxazosin Tablets, USP, 2 mg, 100-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-7328-1 | 3 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0515-2023 | Doxazosin Tablets, USP, 4 mg, 100-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-7149-1 | 4 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0516-2023 | Finasteride Tablets, USP, 5 mg, packaged in: a) 30-count bottles (NDC 68788-6976-3); b) 90-count bottles (NDC 68788-6976-9), Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703. | a) 135 Bottles, b) 24 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0517-2023 | Glimepiride Tablets, USP, 2 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-8095-9 | 17 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0518-2023 | Montelukast Sodium Tablets, USP, 10 mg, packaged in: a) 30-count bottle (NDC 68788-9438-3); b) 60-count bottle (NDC 68788-9438-6); c) 90-count bottle (NDC 68788-9438-9), Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703. | a) 266 Bottles, b) not reported, c) 216 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0519-2023 | Rosuvastatin Tablets, USP, 10 mg, Packaged as: a) 30-count bottle (NDC 68788-7086-3); b) 90-count bottle (NDC 68788-7086-9), Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703. | a) 59 Bottles, b) 77 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0520-2023 | Rosuvastatin Tablets, USP, 5mg, 30-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-7971-3 | 264 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0521-2023 | Pravastatin Sodium Tablets, USP, 20 mg, 90-count bottle, Rx only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-8215-9 | 24 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0522-2023 | Simvastatin Tablets, USP, 10 mg, 90-count bottle, Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703, NDC 68788-9747-9 | 82 Bottles of 90 Tablets | Class II | Ongoing | 12 Apr 2023 |
| D-0523-2023 | Simvastatin Tablets, USP, 80 mg, 90-count bottle, Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703, NDC 68788-9429-9 | 57 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0524-2023 | Simvastatin Tablets, USP, 20 mg, Packaged as: a) 90-count bottle (NDC 68788-9869-9); b) 60-count bottle (NDC 68788-9869-6); c) 30-count bottle (NDC 68788-9869-3), Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703. | a) 305 Bottles, b) 72 Bottles, c) 617 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0525-2023 | Simvastatin Tablets, USP, 40 mg, Packaged as: a) 90-count bottle (NDC 68788-9868-9); b) 60-count bottle (NDC 68788-9868-6); c) 30-count bottle (NDC 68788-9868-3), Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703. | a) 88 Bottles, b) 3 Bottles, c) 175 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0526-2023 | Tadalafil Tablets, USP, 20 mg, 7-count bottle, Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703, NDC 68788-8153-7 | 32 Bottles | Class II | Ongoing | 12 Apr 2023 |
| D-0527-2023 | Glimepiride Tablets USP, 4 mg, 90-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-8066-9 | 15 Bottles | Class II | Ongoing | 12 Apr 2023 |
Context
Other enforcement events for Preferred Pharmaceuticals, Inc.
All 32 events for Preferred Pharmaceuticals, Inc.
Questions and answers
Why was this drug recalled?
FDA's record gives the reason for recall as: "cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection."
What does Class II mean?
FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Where was the product distributed?
FDA's distribution pattern field reads: "USA Nationwide"
Is the recall still ongoing?
FDA lists the status as Ongoing. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.
Where does this data come from?
openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.
Provenance
Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.